AIM ImmunoTech Inc. Common Stock (AIM)

About AIM

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa)…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

19

Website

aimimmuno.com/

Fundamentals

1-day range

$0.25$0.2598

Market cap

$7.32M

P/E (trailing)

—

P/E (forward)

-0.70

EPS (trailing)

$-7.39

Dividend yield

—

Beta

1.31

Avg. volume

10.21M

Forecasts

2 analyst ratings

AIM ImmunoTech Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• AIM

  AIM ImmunoTech Inc. Common Stock

  $0.2558

  ▲ 2.32%
  Market cap $7.32MP/E —
  $0.1901$2.89
• BCAB

  BioAtla Inc. Common Stock

  $1.79

  ▼ 42.99%
  Market cap $5.41MP/E —
  $2.81$71.5
• BCDA

  BioCardia Inc. Common Stock

  $1.16

  ▼ 0.85%
  Market cap $9.45MP/E —
  $0.75$2.29
• PHGE

  BiomX Inc. COmmon Stock

  $0.138

  ▲ 4.55%
  Market cap $4.62MP/E —
  $0.1192$12.29
• CRIS

  Curis Inc. Common Stock

  $1.49

  ▲ 2.76%
  Market cap $10.04MP/E —
  $1.4$39
• VIVS

  VivoSim Labs Inc. Common Stock

  $0.29

  ▲ 0.00%
  Market cap $4.03MP/E —
  $0.2625$5.3
• INTS

  Intensity Therapeutics Inc. Common stock

  $4.25

  ▲ 0.95%
  Market cap $11.51MP/E —
  $3.51$43.5

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $7
  benzinga · 8/20/2026
• Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $7
  Benzinga · 8/20/2026
• AIM ImmunoTech Q2 EPS $(0.43) Misses $(0.18) Estimate, Sales $26.000K Up From $25.000K YoY
  Benzinga · 8/10/2026
• AIM ImmunoTech Announces Final Subjects Receives Last Dose Of Ampligen Under Study Protocol In Phase 2 DURIPANC Clinical Study
  Benzinga · 8/3/2026

• Equels Thomas K · March 12, 2026 · Conversion

  25
• Equels Thomas K · March 12, 2026 · Conversion

  25.0K
• David I. Chemerow · March 12, 2026 · Conversion

  25
• David I. Chemerow · March 12, 2026 · Conversion

  25.0K
• Equels Thomas K · March 6, 2026 · J

  50.0K
• Equels Thomas K · March 6, 2026 · J

  25 @ $25,000
• David I. Chemerow · March 6, 2026 · J

  50.0K
• David I. Chemerow · March 6, 2026 · J

  25 @ $25,000

Institutional Ownership

March 31, 2026

Total shares held

153.2K

Total value held

$44.7K

Institutional holders

16